Elimination of the insulin receptor specifically in osteoprogenitor cells affords the opportunity to study the impact of the IR and its ligand in vivo on bone development, without the metabolic consequences associated with eliminating the IR in all tissues, which consistently leads to hyperinsulinemia. The gene discussed is INSR; the disease is hyperinsulinism.